Sustained reduction of aldosterone in response to the angiotensin receptor blocker Valsartan in patients with chronic heart failure: Results from the Valsartan heart failure trial

Jay N. Cohn, Inder S. Anand, Roberto Latini, Serge Masson, Yann Tong Chiang, Robert Glazer

Research output: Contribution to journalArticlepeer-review

Abstract

Background - Aldosterone has been implicated in the progression of heart failure. The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure. Methods and Results - Plasma aldosterone was measured by radioimmunoassay in core laboratories at baseline and during follow-up in patients assigned to valsartan at a target dose of 160 mg twice daily or placebo. In the placebo group, aldosterone (baseline, 150±160 pg/mL, mean±SD; n = 2025) increased at 4, 12, and 24 months. In the valsartan group, aldosterone (baseline, 137±124 pg/mL, mean±SD; n = 2023) decreased at 4 months and remained suppressed for up to 2 years. At end point (last measurement in each patient), mean aldosterone increased by 17.8±3.0 pg/mL (SEM) (11.9%) in the placebo group and decreased by 23.8±3.0 pg/mL (SEM) (-17.4%) in the in the valsartan group (P

Original languageEnglish
Pages (from-to)1306-1309
Number of pages4
JournalCirculation
Volume108
Issue number11
DOIs
Publication statusPublished - Sep 16 2003

Keywords

  • Angiotensin
  • Heart failure
  • Trials

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Sustained reduction of aldosterone in response to the angiotensin receptor blocker Valsartan in patients with chronic heart failure: Results from the Valsartan heart failure trial'. Together they form a unique fingerprint.

Cite this